Mlp Saglik Hizmetleri As Class B · BIST:MPARK

Mlp Saglik Hizmetleri As Class B — MLP Care — FY2020 Earnings Presentation

28 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Mar 9, 2021

  1. Slide 1: MLP Care 2020 Presentation

    MLP CARE 2020 PRESENTATION MARCH 9TH, 2021

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava

  3. Slide 3: Muharrem Usta, Chairman & CEO

    MUHARREM USTA CHAIRMAN & CEO MLPCARE MEDICALPARK | Lit/nosprtaL

  4. Slide 4: At a Glance: MLP Care 2020 Financial Highlights

    At a Glance: MLP Care 2020 Financial Highlights Adj. EBITDA Revenue TL 4,015 m TL 1,049 m 8% Growth 26% Growth  Revenue growth continued y-o-y despite the (2019: TL 3,704 m) (2019: TL 834 m) challenges of pandemic  EBITDA margin supported by operational performance of hospitals and effective cost

  5. Slide 5: At a Glance: MLP Care Operational Highlights

    At a Glance: MLP Care Operational Highlights Two brands and one concept targeting three different price points with The largest hospital group in 30 Hospitals in consistently outstanding medical service Total Turkey quality Established in 1993, listed on BIST in 2018 ~18,000 Staff 1 ~6,000 Beds in T

  6. Slide 6: # of People with Top-up Insurance Exceeds 1.6 million

    # of People with Top-up Insurance Exceeds 1.6 million # of People with Top-up Insurance in Turkey 12.2020; 1,607 12.2019; 1,354 CAGR 12.2018; 920 (2014-2020) %71.0 2.2015 4.2016 6.2017 8.2018 10.2019 10.2014 12.2014 4.2015 6.2015 8.2015 10.2015 12.2015 2.2016 6.2016 8.2016 10.2016 12.2016 2.2017 4.2

  7. Slide 7: Our Growth Strategy is Intact

    Our Growth Strategy is Intact MLP Care continues its asset light growth strategy Growing our existing business by increasing capacity utilization at large hospitals Expanding in metropolitans through mid- large scale hospitals (min. 100 bed capacity) Quick EBITDA ramp-up through leveraging MLP Care’

  8. Slide 8: A network of hospitals located strategically across Istanbul

    A network of hospitals located strategically across Istanbul VM Medical Park Maltepe Map of Istanbul Location: Maltepe / Istanbul Opening Date: December 2019 TOTAL CAPEX: TL 2.1 million Key Statistics  20k sqm  135 bed capacity  60 policlinic rooms Hospitals with Medical Park Brand  7 operating

  9. Slide 9: Growth Opportunities in Ankara

    Growth Opportunities in Ankara Map of Ankara VM Medical Park Ankara Medical Park Ankara Location: Keçiören/ Ankara Opening Date: March 2020 Hospitals with Medical Park Brand TOTAL CAPEX: Less than TL 1 million Liv Hospital Hospitals with Liv Hospital Brand Ankara Key Statistics  19k sqm  94 bed ca

  10. Slide 10: Growth Opportunities in Gaziantep

    Growth Opportunities in Gaziantep Map of Gaziantep Liv Hospital Gaziantep Location: Şehitkamil / Gaziantep Opening Date: September 2020 TOTAL CAPEX: TL 1.1 million Medical Park Key Statistics Gaziantep  40k sqm  258 bed capacity  70 policlinic rooms Hospitals with Medical Park Brand  8 operating

  11. Slide 11: Planned Opening and M&A's in 2021 – 2022

    Planned Opening and M&A’s in 2021 – 2022 # of Hospitals Liv Hospital İstanbul Target M&A’s (Planned) 5 4 1 25 Medical Park Liv Hospital 2021 Additions 2021-2022 Target M&A's Liv Hospital Location  İstanbul  Metropols Opening Date  ~ Q2 2021  2021-2022 Key Statistics  ~ 50k sqm  4 new hospitals

  12. Slide 12: Accelerated Efforts for Digitalization After Pandemic

    Accelerated Efforts for Digitalization After Pandemic • Instant decision support system with the use of real time data flow will be operational in our hospitals, a first in Turkey. RPA in HR RPA in RPA in Legal Invoice Services Processing RPA in Digital Supply Chain Doctor Digital Support System Dig

  13. Slide 13: Burcu Öztürk, CFO

    BURCU OZTURK CFO MLPCARE MEDICALPARK | Lit/nosprtaL

  14. Slide 14: Revenue Increased 8% in 2020 despite the COVID-19 Impact

    Revenue Increased 8% in 2020 despite the COVID-19 Impact Revenue (TLm) 8.4% 4,015 3,704 21.6% 1,201 988 Q4 2019 Q4 2020 2019 2020 Denotes growth of Revenue vs. the same period of the last year 14

  15. Slide 15: Diversified Revenue Structure Supported the Growth in 2020

    Diversified Revenue Structure Supported the Growth in 2020 2020  Revenue from SSI was up by 33% in Q4 (13%) 2020 (SSI Insurance allows for a wide addressable market, which is c.98% of the (22%) 7% total population) 21% 8%  Self pay increased by 23% in Q4 2020 28%  Revenue from PMI, Top-up & Contr

  16. Slide 16: Revenue Climbs Up After Movement and Travel Restrictions

    Revenue Climbs Up After Movement and Travel Restrictions Domestic Patient Medical Tourism Ancillary Business Revenues Revenues 15.8% (16.4%) (13.1%) 15.1% (21.8%) 25.5% 15.6% 266 3,408 340 9.1% 24.4% 7.8% 1,014 114 74 Q4 2020 2020 Q4 2020 2020 Q4 2020 2020 Revenue Growth Continued in Q4 Gradual reco

  17. Slide 17: Strong Improvement in Both ARPV and ARPP in 2020

    Strong Improvement in Both ARPV and ARPP in 2020 Outpatient Revenues (TLm) Inpatient Revenues (TLm) 9.9% 18.6% 35.2% 39.5% (25.3%) (20.8%) 428 690 (307) (364) 1,215 1,335 2,073 1,747 2019 Volume & Mix Price 2020 2019 Volume & Mix Price 2020 Average Revenue Per Visit (ARPV) Average Revenue Per Protoc

  18. Slide 18: EBITDA Up by 26% in 2020 supported by prudent cost management

    EBITDA Up by 26% in 2020 supported by prudent cost management EBITDA (TLm) 25.8% 17.7% 958 1,049 814 834 21.7% 19.5% 283 265 233 222 Q4 2019 1 Q4 2020 1 2019 1 2020 1 Q4 2019 2 Q4 2020 2 2019 2 2020 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on relevant period and one-off inco

  19. Slide 19: EBITDA Up by 37% in 2020 supported by prudent cost management

    EBITDA Up by 37% in 2020 supported by prudent cost management EBITDA (TLm) 36.5% 791 579 26.4% 212 168 Q4 2019 1 Q4 2020 1 2019 1 2020 1 1Adj. EBITDA: Adj. EBITDA (excluding obligations under operational leases related to IFRS 16). Denotes growth of Adj. EBITDA vs. the same period of the last year 1

  20. Slide 20: Prudent Cost Management

    Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 22.5% 26.1%  Material costs as a % of revenue declined in 2020 due 0.8% to decrease in the share of laboratory business which 0.9% has

  21. Slide 21: Closed Open FC Net Debt Position

    Closed Open FC Net Debt Position FX BASED NET DEBT 1 (in EUR m) 100 NET DEBT 90 80 20201 EUR30m EUR32m 70 equivalent of equivalent of FX Cash FX Cash 60 51 Balance Balance 50 42 40 30 46 20 10 65 - 51 Net Hard 2020 FMT Currency Debt Revenue 46 Converted into TL (in EUR) (in EUR) 0 Nominal Net Debt (

  22. Slide 22: Total Capex Decreased, Operating Cash Flow Improved

    Total Capex Decreased, Operating Cash Flow Improved Maintenance Capex (TLm) Total Capex (TLm) Operating Cash Flow / EBITDA Free Cash Flow / EBITDA 85.7% 79.6% 69.9% 4.7% 4.1% 58.8% 2.3% 899 1.6% 733 173 166 663 490 58 92 2019 2020 2019 2020 2019 2020 2019 2020 % of Revenue % of Revenue % of EBITDA %

  23. Slide 23: Q&A

    Q&A MLPCARE MEDICALPARK | Lit/nosprtaL

  24. Slide 24: Closing Remarks

    Closing Remarks MUHARREM USTA CHAIRMAN & CEO

  25. Slide 25: Thank You!

    Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/

  26. Slide 26: Historical Balance Sheet

    Historical Balance Sheet Audited Audited TLm December 31, 2020 December 31, 2019 Cash and cash equivalents 375 306 Trade receivables 1,155 991 Inventory 113 90 Short term other assets 542 335 Current assets 2,185 1,722 Tangible and intangible fixed assets 1,441 1,327 Right of use assets 257 235 Defe

  27. Slide 27: Historical P&L Statements

    Historical P&L Statements Audited Audited Unaudited Unaudited Change (%) Change (%) TLm 2020 2019 Q4 2020 Q4 2019 Revenue 4,015 3,704 8.4% 1,201 988 21.6% Cost of service (-) (3,058) (2,852) 7.2% (909) (754) 20.6% Gross profit 956 852 12.3% 292 234 24.7% General administration expenses (-) (266) (30

  28. Slide 28: Reconciliation from Reported EBITDA to Adjusted EBITDA

    Reconciliation from Reported EBITDA to Adjusted EBITDA TLm 2020 2019 Q4 2020 Q4 2019 Net profit / (loss) 123 56 71 76 Tax (income) from operations 63 26 25 31 Depreciation and amortization of tangible and intangible fixed assets 252 266 64 68 Total interest expenses/(income) and fair value differenc

MLP Care — FY2020 Earnings Presentation on 6ix